Ultimovacs ASA (ULTI.OL)

NOK 2.76

(14.79%)

Annual Income Statements

(In NOK)
Breakdown 2023 2022 2021 2020 2019 2018
Revenue - - - - - -
Cost of Revenue 2.76 Million 2.64 Million 2.7 Million 2.72 Million 2.06 Million 601 Thousand
Gross Profit -2.76 Million -2.64 Million -2.7 Million -2.72 Million -2.06 Million -601 Thousand
Operating Expenses 215.73 Million 183.63 Million 163.83 Million 124.14 Million 66.21 Million 56.52 Million
Selling, General and Administrative Expenses 61.49 Million 9.24 Million 5.06 Million 3.97 Million 3.65 Million 6.64 Million
Research and Development Expenses 123.83 Million 95.17 Million 96.73 Million 64.66 Million 35.52 Million 16.95 Million
Other Expenses 30.41 Million 79.2 Million 62.03 Million 55.5 Million 27.03 Million 32.92 Million
Cost and Expenses 215.73 Million 183.63 Million 163.83 Million 124.14 Million 66.21 Million 56.52 Million
Operating Income -215.73 Million -183.63 Million -163.83 Million -124.14 Million -61.6 Million -56.52 Million
Interest Expense 382 Thousand - 333 Thousand 240 Thousand 263 Thousand 133 Thousand
Income Tax Expense - -20.89 Million 2.03 Million -3.83 Million -5.31 Million -1.37 Million
Earnings before Tax -189.23 Million -167.79 Million -164.72 Million -120.55 Million -61.16 Million -55.28 Million
Net Income -189.23 Million -146.9 Million -166.75 Million -116.71 Million -55.85 Million -53.9 Million
Earnings Per Share Basic -5.50 -4.29 -5.15 -3.86 -2.44 -3.36
Earnings Per Share Diluted -5.50 -4.29 -5.15 -3.86 -2.44 -3.36
Weighted Average Shares Outstanding 34.39 Million 34.24 Million 32.37 Million 30.26 Million 22.92 Million 16.02 Million
Weighted Average Shares Outstanding (Diluted) 34.39 Million 34.24 Million 32.37 Million 30.26 Million 22.92 Million 16.02 Million
Gross Margin - - - - - -
EBIT Margin - - - - - -
Profit Margin - - - - - -
EBITDA -214.85 Million -164.9 Million -161.68 Million -117.59 Million -58.84 Million -55.92 Million
Earnings Before Tax Margin - - - - - -

Income Statement Charts